Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy.


Journal

Esophagus : official journal of the Japan Esophageal Society
ISSN: 1612-9067
Titre abrégé: Esophagus
Pays: Japan
ID NLM: 101206627

Informations de publication

Date de publication:
01 2020
Historique:
received: 13 04 2019
accepted: 05 09 2019
pubmed: 12 9 2019
medline: 16 7 2021
entrez: 12 9 2019
Statut: ppublish

Résumé

Fistula is one of the known complications of T4 esophageal cancer (T4-EC). The standard treatment for T4-EC is chemoradiotherapy, but detailed data about fistula resulting from chemoradiotherapy in this condition are limited. In particular, radiographic findings of T4-EC with fistula have not been reported. This study assessed the risk factors of fistula based on clinical information on patients with chemoradiotherapy for T4-EC. We retrospectively reviewed the clinical data of 59 T4-EC patients who had squamous cell carcinoma without any fistula before receiving definitive or palliative chemoradiotherapy. A fistula was observed in 18 patients (31%) throughout their clinical course. The overall survival in the fistula group was significantly shorter than that in the non-fistula group (259 vs. 346 days; p = 0.0341). The axial tumor size on computed tomography (CT) was confirmed as an independent risk factor for esophageal fistula in multivariate analysis of stepwise methods [OR 1.226; 95% CI 1.109-1.411; p < 0.0001]. Twelve out of 14 patients with an axial tumor size of 50 mm or greater had developed a fistula. A large tumor size on the axial plane on CT is a risk factor for fistula formation.

Sections du résumé

BACKGROUND AND AIM
Fistula is one of the known complications of T4 esophageal cancer (T4-EC). The standard treatment for T4-EC is chemoradiotherapy, but detailed data about fistula resulting from chemoradiotherapy in this condition are limited. In particular, radiographic findings of T4-EC with fistula have not been reported. This study assessed the risk factors of fistula based on clinical information on patients with chemoradiotherapy for T4-EC.
METHODS
We retrospectively reviewed the clinical data of 59 T4-EC patients who had squamous cell carcinoma without any fistula before receiving definitive or palliative chemoradiotherapy.
RESULTS
A fistula was observed in 18 patients (31%) throughout their clinical course. The overall survival in the fistula group was significantly shorter than that in the non-fistula group (259 vs. 346 days; p = 0.0341). The axial tumor size on computed tomography (CT) was confirmed as an independent risk factor for esophageal fistula in multivariate analysis of stepwise methods [OR 1.226; 95% CI 1.109-1.411; p < 0.0001]. Twelve out of 14 patients with an axial tumor size of 50 mm or greater had developed a fistula.
CONCLUSIONS
A large tumor size on the axial plane on CT is a risk factor for fistula formation.

Identifiants

pubmed: 31506805
doi: 10.1007/s10388-019-00691-y
pii: 10.1007/s10388-019-00691-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-73

Références

Radiology. 1983 Feb;146(2):433-8
pubmed: 6849089
J Clin Oncol. 1999 Sep;17(9):2915-21
pubmed: 10561371
BMC Cancer. 2018 May 18;18(1):573
pubmed: 29776344
Jpn J Clin Oncol. 2004 Oct;34(10):615-9
pubmed: 15591460
J Surg Oncol. 2012 Sep 15;106(4):441-7
pubmed: 22371189
Gastrointest Endosc. 1995 Dec;42(6):501-6
pubmed: 8674918
AJR Am J Roentgenol. 1981 Jun;136(6):1051-6
pubmed: 6786011
World J Surg. 2014 Nov;38(11):2891-7
pubmed: 24952078
Cancer Sci. 2007 Jul;98(7):937-42
pubmed: 17441965
J Clin Oncol. 2002 Mar 1;20(5):1167-74
pubmed: 11870157
Esophagus. 2016;13:110-137
pubmed: 27110229
World J Surg. 2013 Sep;37(9):2180-8
pubmed: 23649529
Int J Clin Oncol. 2011 Aug;16(4):359-65
pubmed: 21347631
Jpn J Clin Oncol. 1996 Oct;26(5):310-5
pubmed: 8895670
Cancer Sci. 2015 Apr;106(4):407-12
pubmed: 25640628
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):134-9
pubmed: 12007951
Br J Cancer. 2016 Nov 22;115(11):1328-1334
pubmed: 27811857
Ann Surg Oncol. 2013 Aug;20(8):2706-12
pubmed: 23504118
Cancer Chemother Pharmacol. 2016 Jul;78(1):91-9
pubmed: 27193097
Ann Oncol. 2014 Mar;25(3):638-43
pubmed: 24492674
Radiat Oncol. 2015 Aug 14;10:171
pubmed: 26269033
Br J Cancer. 2003 Jan 13;88(1):18-24
pubmed: 12556953
J Radiat Res. 2014 Sep;55(5):940-7
pubmed: 24914102
Medicine (Baltimore). 2016 May;95(20):e3699
pubmed: 27196482

Auteurs

Tomoko Katsui Taniyama (TK)

Department of Medical Oncology, Tokyo Saiseikai Mukojima Hospital, Tokyo, Japan.

Takashi Tsuda (T)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan. tatsuda@marianna-u.ac.jp.

Kunihisa Miyakawa (K)

Department of Radiology, St. Marianna University School of Medicine, Kanagawa, Japan.

Hiroyuki Arai (H)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Ayako Doi (A)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Mami Hirakawa (M)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Yoshiki Horie (Y)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Takuro Mizukami (T)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Naoki Izawa (N)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Takashi Ogura (T)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Yu Sunakawa (Y)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Takako Eguchi Nakajima (TE)

Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH